Mirati Therapeutics, Inc.

NasdaqGS:MRTX 주식 보고서

시가총액: US$4.1b

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Mirati Therapeutics 관리

관리 기준 확인 4/4

Mirati Therapeutics' CEO는 Chuck Baum, Nov2012 에 임명되었습니다 의 임기는 11.17 년입니다. 총 연간 보상은 $ 7.42M, 9.2% 로 구성됩니다. 9.2% 급여 및 90.8% 보너스(회사 주식 및 옵션 포함). 는 $ 6.57M 가치에 해당하는 회사 주식의 0.16% 직접 소유합니다. 6.57M. 경영진과 이사회의 평균 재임 기간은 각각 2.5 년과 5.1 년입니다.

주요 정보

Chuck Baum

최고 경영자

US$7.4m

총 보상

CEO 급여 비율9.2%
CEO 임기11.2yrs
CEO 소유권0.2%
경영진 평균 재임 기간2.5yrs
이사회 평균 재임 기간5.1yrs

최근 관리 업데이트

Recent updates

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Oct 05
We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?

Jun 22
Is Mirati Therapeutics (NASDAQ:MRTX) In A Good Position To Invest In Growth?

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

May 17
Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Feb 01
We Think Mirati Therapeutics (NASDAQ:MRTX) Needs To Drive Business Growth Carefully

Some Analysts Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates

Dec 09
Some Analysts Just Cut Their Mirati Therapeutics, Inc. (NASDAQ:MRTX) Estimates

We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth

Oct 08
We Think Mirati Therapeutics (NASDAQ:MRTX) Can Afford To Drive Business Growth

Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?

Sep 11
Is There An Opportunity With Mirati Therapeutics, Inc.'s (NASDAQ:MRTX) 30% Undervaluation?

Mirati: A Potential Blockbuster Stock, Will Need Patience

Sep 08

Mirati jumps 11% as Amgen meets key goal for rival cancer drug

Aug 31

Mirati gains as Amgen posts new combination data for rival cancer drug

Aug 08

Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

Aug 08
Need To Know: Analysts Are Much More Bullish On Mirati Therapeutics, Inc. (NASDAQ:MRTX) Revenues

Mirati: Not Looking Good In 2022, But Stronger Prospects In 2-3 Years

Jun 21

CEO 보상 분석

Chuck Baum 의 보수는 Mirati Therapeutics 의 수익과 비교하여 어떻게 변경되었나요?
날짜총 보상급여회사 수익
Sep 30 2023n/an/a

-US$726m

Jun 30 2023n/an/a

-US$738m

Mar 31 2023n/an/a

-US$737m

Dec 31 2022US$7mUS$685k

-US$741m

Sep 30 2022n/an/a

-US$738m

Jun 30 2022n/an/a

-US$645m

Mar 31 2022n/an/a

-US$634m

Dec 31 2021US$18mUS$662k

-US$582m

Sep 30 2021n/an/a

-US$483m

Jun 30 2021n/an/a

-US$491m

Mar 31 2021n/an/a

-US$407m

Dec 31 2020US$12mUS$615k

-US$358m

Sep 30 2020n/an/a

-US$329m

Jun 30 2020n/an/a

-US$296m

Mar 31 2020n/an/a

-US$259m

Dec 31 2019US$8mUS$597k

-US$213m

Sep 30 2019n/an/a

-US$169m

Jun 30 2019n/an/a

-US$142m

Mar 31 2019n/an/a

-US$125m

Dec 31 2018US$5mUS$580k

-US$98m

Sep 30 2018n/an/a

-US$88m

Jun 30 2018n/an/a

-US$77m

Mar 31 2018n/an/a

-US$67m

Dec 31 2017US$2mUS$563k

-US$70m

보상 대 시장: Chuck 의 총 보상 ($USD 7.42M )은 US 시장에서 비슷한 규모의 회사의 평균 수준입니다( $USD 6.80M ).

보상과 수익: Chuck 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Chuck Baum (65 yo)

11.2yrs

테뉴어

US$7,420,213

보상

Dr. Charles M. Baum, M.D., Ph D., also known as Chuck, is a Director of Acrivon Therapeutics, Inc. from June 2023. Dr. Baum is an Independent Director of Poseida Therapeutics, Inc. from May 16, 2022.He se...

리더십 팀

이름위치테뉴어보상소유권
Charles Baum
Founder11.2yrsUS$7.42m0.16%
$ 6.6m
James Christensen
Executive VP & Chief Scientific Officer10yrsUS$5.01m0.082%
$ 3.4m
Alan Bart Sandler
Executive VP & Chief Medical Officer1.2yrsUS$5.30m0.014%
$ 587.2k
Aaron Ondrey
Chief Financial Officerless than a year데이터 없음0.056%
$ 2.3m
Betsy Gelfand
Chief Accounting Officerless than a year데이터 없음데이터 없음
John Moriarty
Chief Legal Officer & Corporate Secretaryless than a year데이터 없음데이터 없음
Peter Lee
Chief Compliance Officer2yrs데이터 없음데이터 없음
Michael Paolucci
Chief People Officer2yrs데이터 없음데이터 없음
Benjamin Hickey
Chief Commercial Officer4yrsUS$6.93m0.040%
$ 1.6m
Kelly Covello
VP & Head of Medical Affairs3.8yrs데이터 없음데이터 없음
Ryan Asay
VP & Head of Corporate Affairs3.8yrs데이터 없음데이터 없음
Susan Welsh
Senior VP of Pharmacovigilance & Chief Safety Officer3yrs데이터 없음데이터 없음

2.5yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: MRTX 의 관리팀은 경험 ( 2.5 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름위치테뉴어보상소유권
Charles Baum
Founder11.2yrsUS$7.42m0.16%
$ 6.6m
Bruce Leonard Carter
Independent Director7.3yrsUS$700.41k0.0086%
$ 353.3k
George Demetri
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Faheem Hasnain
Chairman & Lead Independent Director4.9yrsUS$979.79k0.012%
$ 511.8k
Julie Michele Cherrington
Independent Director4.6yrsUS$697.91k0%
$ 0
Stephen Baylin
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Lillian Siu
Member of Scientific Advisory Boardno data데이터 없음데이터 없음
Aaron Davis
Independent Director5.1yrsUS$677.91k0.061%
$ 2.5m
Pasi Antero Janne
Member of Scientific Advisory Board5yrs데이터 없음데이터 없음
Craig Johnson
Independent Director10.3yrsUS$702.91k0.0086%
$ 353.3k
Channing Der
Member of Scientific Advisory Board5yrs데이터 없음데이터 없음
Maria Martinez-Davis
Independent Director5.1yrsUS$695.41k0.0086%
$ 353.3k

5.1yrs

평균 재임 기간

65yo

평균 연령

경험이 풍부한 이사회: MRTX 의 이사회는 경험(평균 재직 기간 5.1 년)으로 간주됩니다.